Back
Article
HC Wainwright & Co. Maintains Buy on Nektar Therapeutics, Raises Price Target to $165
Benzinga Newsdesk  |  Feb 10, 2026 18:26  |  Source: www.benzinga.com
HC Wainwright & Co. analyst Arthur He maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $135 to $165.
Comments
  • No comments yet. Be the first to comment!

Login to comment